Three new drugs for type 2 diabetes

Drug and Therapeutics Bulletin

Volumn 46, Issue 7, 2008, Pages 49-52

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; NITRILE; PEPTIDE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ACUTE PANCREATITIS; ADD ON THERAPY; CLINICAL TRIAL; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG WITHDRAWAL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEADACHE; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHINOPHARYNGITIS; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ARTICLE; METABOLISM; TREATMENT OUTCOME;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; NITRILES; PEPTIDES; PYRAZINES; PYRROLIDINES; TREATMENT OUTCOME; TRIAZOLES; VENOMS;

EID: 55049124289     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2008.06.0014     Document Type: Review

References (19)

1. National Collaborating Centre for Chronic Conditions, 2008. Type 2 diabetes: national clinical guidelines for management in primary care [online]. London: Royal College of Physicians. Available http://www.nice.nhs.uk/ nicemedia/pdf/CG66diabetesfullguideline.pdf [Accessed 23 June 2008].
2. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
4. Richter B et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes-mellitus. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006739. DOI: 10.1002/14651858.CD006739.pub2 [Date of most recent substantive amendment: 20 February 2007].
5. Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen. Summary of product characteristics, EU. Eli Lilly Nederland BV, January 2008.
6. Buse JB et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
7. DeFronzo RA et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.
8. Kendall DM et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.
9. Zinman B et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-85.
10. Heine RJ et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-69.
11. Nauck MA et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-67.
12. Barnett AH et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomised, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-48.
13. Klonoff DC et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-86.
14. Amori RE et al. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
15. MHRA. Exenatide (Byetta): risk of acute pancreatitis. Drug Safety Update 2008; 1(10): 5.
16. Januvia 100mg film-coated tablets. Summary of product characteristics, EU. Merck Sharp & Dohme Ltd, February 2008.
17. Galvus 50mg tablets. Summary of product characteristics, EU. Novartis Europharm Limited, February 2008.
18. Eucreas 50 mg/850 mg and 50 mg/1000 mg film-coated tablets. Summary of product characteristics, EU. Novartis Europharm Limited, February 2008.
19. Garber AJ et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obesity Metabolism 2008; Feb 18: [Epub ahead of print].